Search

everythinglearnresearchcommunity

for

Search:↓

A patient with a nerve disorder died from infection complications after developing insulin resistance from a treatment.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.

A woman with severe angioedema improved significantly after treatment with rituximab.

Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.

A patient's grey hair regained color during treatment with adalimumab.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.

Mogamulizumab, a skin cancer drug, may cause hair loss similar to alopecia areata.

Ixekizumab successfully treated a rare hair loss condition, leading to complete hair regrowth.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Ocrelizumab may cause total body hair loss in some patients.

Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

Dexamethasone-primed stem cell media shows promise in treating lupus by reducing symptoms and inflammation.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.

Efalizumab can cause unexpected excessive hair growth.